Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kura Oncology reports Q4 loss, highlights ziftomenib's AML potential

Kura Oncology's Q4 2022 performance reflects increased R&D expenses and a net loss, offset by a strong cash position supporting operations.
The company's focus on ziftomenib's positive trial data, combination studies, and patient-centric strategies positions it for future growth.
Challenges lie in managing treatment complexities, strategic resource allocation, and balancing commercial value with patient benefit.
Opportunities include upcoming milestones, exploration of combination therapies, and regulatory advancements for ziftomenib.

Kura Oncology sees positive results with ziftomenib in Q1

Kura Oncology's Q1 2023 earnings call highlighted the promising performance of ziftomenib in AML patients, supported by strong Phase 1 trial data and strategic plans for combination studies.
While facing challenges in competitive differentiation and trial execution, the company's financial stability and focus on methodical drug development underscore its long-term potential.
Opportunities lie in achieving key milestones, exploring new therapeutic applications, and leveraging a competitive edge in the menin inhibitor space for future growth and success.

Kura Oncology reports Q2 loss, sees growth in clinical trials

Kura Oncology's Q2 2023 performance reflects increased expenses but promising clinical outcomes, with strong enrollment and positive data in key trials.
Strategic strengths lie in combination studies, diversified indications, and positive trial results, positioning the company for future growth and market expansion.
Challenges include resource constraints, research prioritization, and evolving resistance issues, necessitating adaptive strategies and efficient resource management.
Opportunities for Kura Oncology include collaborations, out-licensing, and program expansions, offering avenues for operational efficiency and revenue growth.

Kura Oncology's ziftomenib shows promise in acute leukemias, financials stable

Kura Oncology's Q3 performance reflects increased expenses but maintains a strong financial position.
The company's lead drug candidate, ziftomenib, shows promise in acute leukemias, with positive response rates.
Strategic strengths include progress with menin inhibitors, successful combination approaches, and clinical collaborations.
Challenges lie in meeting enrollment timelines, addressing efficacy questions, and balancing program investments.

Kura Oncology reports promising clinical data and financial stability

Kura Oncology's Q4 2023 performance showcased positive clinical data and financial stability, positioning the company well for future growth.
While challenges in data interpretation and differentiation exist, opportunities in milestone achievements and patient-focused therapies are on the horizon.
The company's strategic focus on early therapy lines and combinability of menin inhibitors highlight its strengths in the competitive market landscape.

Kura Oncology reports promising results for ziftomenib in Q1

Kura Oncology's Q1 2024 performance reflects increased R&D expenses and promising results for ziftomenib.
Strengths lie in FDA support, encouraging safety profiles, and ongoing combo dose escalation trials.
Challenges include patient characteristics impacting therapy duration and strategic resource allocation.
Opportunities include upcoming milestones, solid tumor data disclosure, and competitor monitoring for market insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). FDA granted BTD for ziftomenib based on data from Kura's ongoing KOMET-001 clinical trial in patients with R/R NPM1-mutant AML.

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2024 Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 11:30 a.m. ET / 8:30 a.m. PT on April 17, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event.

Kura Oncology to Participate in Stifel Targeted Oncology Forum

– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter –

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript

– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome –

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML –

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive preliminary data for a Phase 1 study of its Ziftomenib “in combination with standards of care”. Ziftomenib trial pushes Kura Oncology stock up The dose-escalation trial studied the combination in patients of acute myeloid leukemia.

Kura Oncology stock jumped another 20% on Tuesday: here's why

– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of patients remain on trial as of data cutoff, including all NPM1-m patients – – 200 mg dose of ziftomenib cleared in ven/aza cohorts, enrollment at 400 mg dose ongoing – – Management to host virtual investor event today at 8:00 a.m. ET – SAN DIEGO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preliminary clinical data from the first 20 patients in KOMET-007, a Phase 1 dose-escalation trial of the Company's potent and selective menin inhibitor, ziftomenib, in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML).

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Kura received a $150 million investment Wednesday — a week before it unveils the test results for a cancer drug — and Kura stock flew.

Kura Oncology Rockets 39% Before Unveiling Cancer Drug Test Results — Here's Why

– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma cash, cash equivalents and investments expected to provide runway into 2027 – – Management to host virtual investor event at 8:00 a.m. ET on January 30 to highlight preliminary combination data for ziftomenib – SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has agreed to sell 1,376,813 shares of its common stock at a price of $17.25 per share, representing a premium of approximately 29% to Kura's closing price on January 23, 2024, and pre-funded warrants to purchase 7,318,886 shares of its common stock at price per pre-funded warrant of $17.2499 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement.

Kura Oncology Announces Oversubscribed $150 Million Private Placement

Kura Oncology is an oncology-focused biotech developing targeted therapies for various forms of cancer with high unmet need. Their pipeline includes ziftomenib for AML, with promising phase 2 results and a potential data readout in 2024. They are also developing tipifarnib for HRAS-mutated HNSCC, with breakthrough therapy designation and positive response rates in early trials.

Kura Oncology: Riding The Menin Hype Wave In AML Therapy

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura's menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit at 2:00 p.m. ET / 11:00 a.m. PT on Tuesday, December 5, 2023.

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Pete De Spain - Head of Investor Relations Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President of Finance & Accounting Conference Call Participants Jason Zemansky - Bank of America Peter Lawson - Barclays Roger Song - Jefferies Li Watsek - Cantor Fitzgerald Jeet Mukherjee - BTIG Phil Nadeau - TD Cowen Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2023 Kura Oncology Inc. Earnings Conference Call. At this time, all lines are in listen-only mode.

Kura Oncology, Inc. (KURA) Q3 2023 Earnings Call Transcript

– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of ziftomenib anticipated early in first quarter of 2024 – – First patient dosed in FIT-001 dose-escalation study of next-generation FTI, KO-2806 – – Clinical collaboration with Mirati to evaluate KO-2806 and adagrasib in KRASG12C-mutated NSCLC – – $452.6 million in cash, cash equivalents and investments provide runway to mid-2026 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2023 financial results and provided a corporate update.

Kura Oncology Reports Third Quarter 2023 Financial Results

– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 – – Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 –

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences.

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the close of U.S. financial markets on Thursday, November 2, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Third Quarter 2023 Financial Results

– Phase 1 dose-escalation study to evaluate KO-2806 as a monotherapy and in combination with targeted therapies in KRASG12C-mutant NSCLC and ccRCC –

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

– Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR – – Data validate activity of farnesyltransferase inhibitors and support rapid advancement of KO-2806 into combinations with targeted therapies in large solid tumor indications – – Results to be presented in late-breaking oral session at 2023 ESMO Congress on Saturday – SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease is recurrent or metastatic and has progressed after prior therapy. These clinical results are being featured during a late-breaking oral session at the 2023 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in a presentation titled, “A phase 2 study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study).

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Kura Oncology (KURA) a New Buy Stock

– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12 D inhibitors –

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors –

News for Kura Oncology Stock (KURA)